Abstract
Mini-gastric bypass (MGB) is a safe, effective, and reversible procedure for patients with type II diabetes mellitus (T2DM) and morbid obesity. Less is known, however, about its long-term effects in patients with a body mass index (BMI) <35kg/m(2). From February 2007 to February 2014, 1468 patients underwent MGB at our institution, including 983 with T2DM. Of these, 128 (82 women), of mean age 41.6 ± 10.2years, had a BMI of 30-35kg/m(2). Prospectively collected data were analyzed retrospectively. Factors assessed included disease duration, family history, medication use, remission, and biochemical indicators, including fasting plasma glucose, glycosylated hemoglobin (HbA1c), serum insulin, and C-peptide concentrations. Remission of T2DM was defined as HbA1c <6.0% without medication. Prior to surgery, patients had a mean BMI of 33.4 ± 3.3kg/m(2), mean waist circumference of 104.5 ± 8.2cm, mean C-peptide concentration of 3.4 ± 1.2ng/ml, and mean T2DM duration of 6.5 ± 3.1years. Within 6months of MGB, 95% of these patients had attained HbA1c <7%. Complete remission rates at 1, 2, and 7years were 64, 66, and 53%, respectively. Mean HbA1c decreased from 10.7 ± 1.5% at baseline to 6.2 ± 0.5% at 1year, 5.4 ± 1.2% at 3years, and 5.7 ± 1.8% at 7years. No deaths occurred, but two (1.6%) patients experienced major complications. MGB provides good, long-term control of T2DM in patients with class I obesity. Early intervention results in higher remission rates.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call